| Imaging drugs with and without clinical analgesic efficacy J Upadhyay, J Anderson, AJ Schwarz, A Coimbra, R Baumgartner, ... Neuropsychopharmacology 36 (13), 2659-2673, 2011 | 72 | 2011 |
| Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of μ-opioid receptors and dynamin-2 M Pawar, P Kumar, S Sunkaraneni, S Sirohi, EA Walker, BC Yoburn European journal of pharmacology 563 (1-3), 92-101, 2007 | 70 | 2007 |
| Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine J Upadhyay, J Anderson, R Baumgartner, A Coimbra, AJ Schwarz, ... Neuroimage 59 (4), 3762-3773, 2012 | 54 | 2012 |
| Hydromorphone efficacy and treatment protocol impact on tolerance and μ-opioid receptor regulation P Kumar, S Sunkaraneni, S Sirohi, SV Dighe, EA Walker, BC Yoburn European journal of pharmacology 597 (1-3), 39-45, 2008 | 53 | 2008 |
| Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects L Becerra, J Upadhyay, PC Chang, J Bishop, J Anderson, R Baumgartner, ... Journal of Pharmacology and Experimental Therapeutics 345 (1), 41-51, 2013 | 42 | 2013 |
| Pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults SC Hopkins, S Sunkaraneni, E Skende, J Hing, JA Passarell, A Loebel, ... Clinical Drug Investigation 36, 137-146, 2016 | 26 | 2016 |
| Getting innovative therapies faster to patients at the right dose: impact of quantitative pharmacology towards first registration and expanding therapeutic use S Nayak, O Sander, N Al‐Huniti, D de Alwis, A Chain, M Chenel, ... Clinical Pharmacology & Therapeutics 103 (3), 378-383, 2018 | 23 | 2018 |
| Population Pharmacokinetic Evaluation and Missed‐Dose Simulations for Eslicarbazepine Acetate Monotherapy in Patients With Partial‐Onset Seizures S Sunkaraneni, D Blum, E Ludwig, V Chudasama, J Fiedler‐Kelly, ... Clinical pharmacology in drug development 7 (3), 287-297, 2018 | 14 | 2018 |
| Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures S Sunkaraneni, E Ludwig, J Fiedler-Kelly, S Hopkins, G Galluppi, D Blum Journal of Pharmacokinetics and Pharmacodynamics 45, 649-658, 2018 | 11 | 2018 |
| Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters BE Gidal, S Mintzer, M Schwab, R Schutz, J Kharidia, D Blum, T Grinnell, ... Epilepsy Research 135, 64-70, 2017 | 11 | 2017 |
| Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate BE Gidal, MP Jacobson, E Ben‐Menachem, M Carreño, D Blum, ... Acta Neurologica Scandinavica 138 (3), 203-211, 2018 | 8 | 2018 |
| A pharmacokinetic study comparing eslicarbazepine acetate administered orally as a crushed or intact tablet in healthy volunteers S Sunkaraneni, J Kharidia, R Schutz, D Blum, H Cheng Clinical Pharmacology in Drug Development 5 (4), 278-284, 2016 | 6 | 2016 |
| Eslicarbazepine acetate monotherapy: a population pharmacokinetic analysis B Abou-Khalil, I Ali, A Shah, J Fiedler-Kelly, E Ludwig, S Sunkaraneni, ... Epilepsy Curr 15 (Suppl 1), 150-151, 2015 | 6 | 2015 |
| Relationship between exposure and efficacy of eslicarbazepine acetate monotherapy J Rogin, AJ Cole, L Strom, J Passarell, J Fiedler-Kelly, E Ludwig, D Blum, ... Epilepsy Curr 15 (Suppl 1), 145-146, 2015 | 6 | 2015 |
| Revumenib monotherapy in patients with relapsed/refractory kmt2ar acute leukemia: Topline efficacy and safety results from the pivotal augment-101 Phase 2 study I Aldoss, GC Issa, M Thirman, J DiPersio, M Arellano, JS Blachly, ... Blood 142, LBA-5, 2023 | 4 | 2023 |
| Population Pharmacokinetics and Exposure–Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial‐Onset Seizures S Sunkaraneni, EA Ludwig, JA Passarell, D Blum, T Grinnell, ... The Journal of Clinical Pharmacology 58 (7), 927-938, 2018 | 4 | 2018 |
| Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: efficacy and safety results from the Augment-101 phase 1/2 study I Aldoss, GC Issa, MJ Thirman, J DiPersio, M Arellano, JS Blachly, ... Blood 142, 2907, 2023 | 3 | 2023 |
| Population pharmacokinetic evaluation of eslicarbazepine acetate for adjunctive therapy in refractory partial onset seizures Q Lu, E Ludwig, J Fiedler-Kelly, G Maier, D Blum, J Kharidia AAPS Annual Meeting and Exposition, San Antonio, TX, 10-14, 2013 | 2 | 2013 |
| Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy S Sunkaraneni, JA Passarell, EA Ludwig, J Fiedler-Kelly, JK Pitner, ... Clinical Pharmacology: Advances and Applications, 65-72, 2017 | 1 | 2017 |
| Modeling and Simulation Strategy to Support Eslicarbazepine Acetate (ESL) Pediatric Dose Selection in the Treatment of Partial Onset Seizures Based on Matching Adult Exposures … S Sunkaraneni, S Bihorel, S Hopkins, J Fiedler-Kelly, E Ludwig, ... Neurology 88 (16 Supplement), 2017 | 1 | 2017 |
